Balyasny Asset Management
ADVM

Balyasny Asset Management’s Adverum Biotechnologies ADVM Stock Holding History

Balyasny Asset Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-14,198
Closed -$201K – 2516
2024
Q1 		$201K Buy
+14,198
New +$216K ﹤0.01% 2404
2022
Q4 		– Sell
-3,273
Closed -$31K – 2731
2022
Q3 		$31K Buy
3,273
+911
+39% +$12K ﹤0.01% 2529
2022
Q2 		$28K Buy
+2,362
New +$24.7K ﹤0.01% 2435
2016
Q1 		– Sell
-64,498
Closed -$6.14M – 1246
2015
Q4 		$6.14M Buy
64,498
+19,333
+43% +$1.7M 0.04% 466
2015
Q3 		$3.72M Buy
45,165
+13,701
+44% +$1.75M 0.03% 566
2015
Q2 		$5.11M Buy
+31,464
New +$10.6M 0.03% 580

Other funds holding ADVM

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Balyasny Asset Management's ADVM Position: Q2 2024 in Review

Balyasny Asset Management sold out of Adverum Biotechnologies (ADVM) in Q2 2024, closing a stake of 14,198 shares — an estimated $201K sold.

Balyasny Asset Management first reported a position in ADVM in Q2 2015 and held it in 6 quarters. The position peaked at $6.14M in Q4 2015. 68 funds tracked by Wall St. Rank hold ADVM as of Q2 2024.

  • Balyasny Asset Management reported no remaining Adverum Biotechnologies position as of Q2 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 14,198 Adverum Biotechnologies shares in Q2 2024, an estimated $201K.
  • Balyasny Asset Management first reported a position in Adverum Biotechnologies in Q2 2015 and held it in 6 quarters.
  • Balyasny Asset Management's Adverum Biotechnologies position peaked at $6.14M in Q4 2015.
  • 68 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2024.

Based on Balyasny Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.